Servier

A phase 3 trial comparing an investigational combination with standard care for advanced colorectal cancer failed to meet its primary endpoint of OS. The trial included 441 patients with PD-L1-positive, microsatellite stable metastatic colorectal cancer. The experimental combination of favezelimab and pembrolizumab showed no OS improvement compared to standard care, with a safety profile consistent with prior reports.

Biologics by McKesson selected by Servier as a limited specialty pharmacy provider for VORANIGO (vorasidenib), a targeted drug for Grade 2 IDH-mutant gliomas, approved by the FDA on August 6, 2024.

OPM announces H1 2024 results: OPM-101 Phase 1 success, OPM-201 nearing Phase 1 completion, €2M capital increase, €8.5M public funding secured, €9.6M cash position, and €3.6M R&D investments.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

DelveInsight's 'Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024' covers 50+ companies and 75+ pipeline drugs, including clinical and nonclinical stage products, with therapeutic assessments by product type, stage, route of administration, and molecule type. Key companies and therapies highlighted.

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.

Preoperative chemoradiotherapy did not improve survival over perioperative chemotherapy alone in resectable gastric and gastroesophageal junction adenocarcinoma, according to TOPGEAR data. Median overall survival was 46.4 months vs 49.4 months, with no significant differences in progression-free survival. However, preoperative chemoradiotherapy significantly improved pathological outcomes, including complete response rates and tumor downstaging.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Three biotech IPOs priced; Voranigo, a brain cancer pill, offers new hope; GLP-1 drugs show potential for type 1 diabetes; Gilead's lenacapavir reduces HIV infection risk; Summit's immunotherapy success discussed; Senators scrutinize misleading drug promotion; insurers scale back on Medicare Advantage; Ozempic sales lead to insurer demands for refunds; compounded semaglutide raises public health concerns.

Digital twins in biotechnology, valued at $15 billion in 2023, optimize biomanufacturing and drug discovery by modeling biological entities. Challenges include large data sets and regulatory uncertainties, which could be addressed by generative AI. Commercial offerings and open-source technologies like Aitia, DeepLife, and Somite Therapeutics demonstrate digital twins' potential in disease modeling, cellular response prediction, and protocol optimization for cell replacement therapy. Digital twin ecosystems, such as those studied by Genzeva and Rylti, aim to model multiscale biological complexity, overcoming data challenges and offering insights into disease mechanisms.